A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA.

Trial Profile

A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Vascular endothelial growth factor 121 gene therapy (Primary)
  • Indications Coronary artery disease; Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Planned end date changed from 1 May 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 20 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top